The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.